Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JT001 (VV116) in Healthy Caucasian Subjects
NCT05355077Phase 1Withdrawn
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 1, open-label trial of deuremidevir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shanghai Vinnerna Biosciences Co., Ltd. Primary endpoint: Pharmacokinetics of JT001 and metabolite 116-N1 at Day 6. Planned start May 2022; status: withdrawn.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05355077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355077.